Compare PETS & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PETS | BNTC |
|---|---|---|
| Founded | 1996 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 344.4M |
| IPO Year | 2003 | 2020 |
| Metric | PETS | BNTC |
|---|---|---|
| Price | $1.06 | $9.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $23.29 |
| AVG Volume (30 Days) | 110.7K | ★ 177.7K |
| Earning Date | 11-10-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $273,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.24 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.06 | $7.89 |
| 52 Week High | $4.10 | $14.39 |
| Indicator | PETS | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 28.30 | 50.37 |
| Support Level | N/A | $8.14 |
| Resistance Level | $1.27 | $9.29 |
| Average True Range (ATR) | 0.06 | 0.63 |
| MACD | 0.01 | 0.17 |
| Stochastic Oscillator | 0.00 | 56.50 |
PetMed Express Inc is a nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, foods, supplements, supplies, and vet services for dogs, cats, and horses. It markets and sells directly to consumers through its websites, toll-free numbers, and mobile application, offering convenience, price, speed of delivery, and customer service. It provides access to branded pharmaceuticals, generic medications, compounded prescription medications, over-the-counter health and wellness products, prescription and non-prescription food, pharmacy fulfillment, and AutoShip capabilities. Its digital platform offers pet healthcare solutions for chronic conditions, including allergies, arthritis, anxiety, kidney-related conditions, and hyperthyroidism.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.